Role of bridging therapy during chimeric antigen receptor T cell therapy

被引：27

作者：

Bhaskar, Shakthi T. ^{[1
]}

Dholaria, Bhagirathbhai R. ^{[1
]}

Sengsayadeth, Salyka M. ^{[1
]}

Savani, Bipin N. ^{[1
]}

Oluwole, Olalekan O. ^{[1
,2
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN 37212 USA

[2] Vanderbilt Univ, Med Ctr, Div Hematol Oncol, Nashville, TN 37212 USA

来源：

EJHAEM | 2022年 / 3卷

关键词：

bridging therapy; chimeric antigen receptor T cell therapy; hematologic malignancies; LYMPHOMA; TISAGENLECLEUCEL; CHEMOTHERAPY; OUTCOMES;

D O I：

10.1002/jha2.335

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Chimeric antigen receptor (CAR) T-cell therapy has been approved for use in several relapsed/refractory hematologic malignancies and has significantly improved outcomes for these diseases. A number of different CAR T products are now being used in clinical practice and have demonstrated excellent outcomes to those in clinical trials. However, increased real-world use of CAR T therapy has uncovered a number of barriers that can lead to significant delays in treatment. As a result, bridging therapy has become a widely used tool to stabilize or debulk disease between leukapheresis and CAR T cell administration. Here we review the available data regarding bridging therapy, with a focus on patient selection, choice of therapy, timing of therapy, and potential pitfalls.

引用

页码：39 / 45

页数：7

共 30 条

[1] Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study [J].

Abramson, Jeremy S. ;

Palomba, M. Lia ;

Gordon, Leo I. ;

Lunning, Matthew A. ;

Wang, Michael ;

Arnason, Jon ;

Mehta, Amitkumar ;

Purev, Enkhtsetseg ;

Maloney, David G. ;

Andreadis, Charalambos ;

Sehgal, Alison ;

Solomon, Scott R. ;

Ghosh, Nilanjan ;

Albertson, Tina M. ;

Garcia, Jacob ;

Kostic, Ana ;

Mallaney, Mary ;

Ogasawara, Ken ;

Newhall, Kathryn ;

Kim, Yeonhee ;

Li, Daniel ;

Siddiqi, Tanya .

LANCET, 2020, 396 (10254) :839-852

[2] Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient Administration [J].

Alexander, Maurice ;

Culos, Kathryn ;

Roddy, Julianna ;

Shaw, J. Ryan ;

Bachmeier, Christina ;

Shigle, Terri Lynn ;

Mahmoudjafari, Zahra .

TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (07) :558-570

[3]

[Anonymous], FISCAL YEAR FY 2020

[4] National Coverage Analysis of CAR-T Therapies - Policy, Evidence, and Payment [J].

Bach, Peter B. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (15) :1396-1398

[5]

Bachier CR, 2020, J CLIN ONCOL, V38

[6] Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion [J].

Bishop, Michael R. ;

Maziarz, Richard T. ;

Waller, Edmund K. ;

Jaeger, Ulrich ;

Westin, Jason R. ;

McGuirk, Joseph P. ;

Fleury, Isabelle ;

Holte, Harald ;

Borchmann, Peter ;

del Corral, Christopher ;

Tiwari, Ranjan ;

Anak, Oezlem ;

Awasthi, Rakesh ;

Pacaud, Lida ;

Romanov, Vadim V. ;

Schuster, Stephen J. .

BLOOD ADVANCES, 2019, 3 (14) :2230-2236

[7] Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study [J].

Crump, Michael ;

Neelapu, Sattva S. ;

Farooq, Umar ;

Van den Neste, Eric ;

Kuruvilla, John ;

Westin, Jason ;

Link, Brian K. ;

Hay, Annette ;

Cerhan, James R. ;

Zhu, Liting ;

Boussetta, Sami ;

Feng, Lei ;

Maurer, Matthew J. ;

Navale, Lynn ;

Wiezorek, Jeff ;

Go, William Y. ;

Gisselbrecht, Christian .

BLOOD, 2017, 130 (16) :1800-1808

[8] Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy [J].

Gandhi, Ujjawal H. ;

Cornell, Robert F. ;

Lakshman, Arjun ;

Gahvari, Zhubin J. ;

McGehee, Elizabeth ;

Jagosky, Megan H. ;

Gupta, Ridhi ;

Varnado, William ;

Fiala, Mark A. ;

Chhabra, Saurabh ;

Malek, Ehsan ;

Mansour, Joshua ;

Paul, Barry ;

Barnstead, Alyssa ;

Kodali, Saranya ;

Neppalli, Amarendra ;

Liedtke, Michaela ;

Narayana, Swapna ;

Godby, Kelly N. ;

Kang, Yubin ;

Kansagra, Ankit ;

Umyarova, Elvira ;

Scott, Emma C. ;

Hari, Parameswaran ;

Vij, Ravi ;

Usmani, Saad Z. ;

Callander, Natalie S. ;

Kumar, Shaji K. ;

Costa, Luciano J. .

LEUKEMIA, 2019, 33 (09) :2266-2275

[9] Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation [J].

Goekbuget, Nicola ;

Stanze, Daniel ;

Beck, Joachim ;

Diedrich, Helmut ;

Horst, Heinz-August ;

Huettmann, Andreas ;

Kobbe, Guido ;

Kreuzer, Karl-Anton ;

Leimer, Lothar ;

Reichle, Albrecht ;

Schaich, Markus ;

Schwartz, Stefan ;

Serve, Hubert ;

Starck, Michael ;

Stelljes, Matthias ;

Stuhlmann, Reingard ;

Viardot, Andreas ;

Wendelin, Knut ;

Freund, Mathias ;

Hoelzer, Dieter .

BLOOD, 2012, 120 (10) :2032-2041

[10] Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy [J].

Hay, Kevin A. ;

Hanafi, Laila-Aicha ;

Li, Daniel ;

Gust, Juliane ;

Liles, W. Conrad ;

Wurfel, Mark M. ;

Lopez, Jose A. ;

Chen, Junmei ;

Chung, Dominic ;

Harju-Baker, Susanna ;

Cherian, Sindhu ;

Chen, Xueyan ;

Riddell, Stanley R. ;

Maloney, David G. ;

Turtle, Cameron J. .

BLOOD, 2017, 130 (21) :2295-2306

← 1 2 3 →